Actively Recruiting
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Led by M.D. Anderson Cancer Center · Updated on 2026-04-24
300
Participants Needed
1
Research Sites
576 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing or kill them.
CONDITIONS
Official Title
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with metastatic colorectal cancer or pancreatic ductal adenocarcinoma
- Planned or completed complete surgical removal of metastatic tumors (metastatectomy) or planned primary tumor resection for pancreatic cancer
- Any number of prior therapies before tissue collection
- Adequate tumor tissue available for vaccine development
- ECOG performance status of 0 or 1
- Life expectancy greater than 12 months for Cohort C and greater than 9 months for Cohort D
- Adequate organ and marrow function
- Able and willing to sign informed consent
- Women of childbearing potential and men agree to use effective contraception during and after study participation
- For Cohort C: agreement to have post-operative blood draw for ctDNA testing within 6 weeks after surgery
You will not qualify if you...
- History of HIV or AIDS
- Presence of brain metastases
- Serious autoimmune diseases
- Use of chronic immune suppressive drugs
- Uncontrolled illnesses such as active infections, heart failure, unstable angina, cardiac arrhythmia, or psychiatric/social conditions limiting study compliance
- Pregnant or breastfeeding women or positive pregnancy test at enrollment
- History of pneumonitis requiring steroids, interstitial lung disease, or active non-infectious pneumonitis
- Known active tuberculosis
- Allergies to study drugs or components
- Other progressing cancers requiring treatment
- Active blood clotting disorders
- Recent arterial thrombosis within 3 months prior to study treatment
- History of severe heart failure (NYHA Class 3-4) or recent heart attack within 6 months
- Known active Hepatitis B or C infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here